ixigo Partners with Uber and redBus to Integrate Cab and Bus Bookings in Train App BASISpro Goes Live Base58Labs Rolls Out Crypto Arbitrage Trading Platform SmallCap Biotech Stock Watch AnalystSelected Opportunities in the Emerging Therapeutics Space Proposed Legislation Seeks YearRound E15 Ethanol Blends to Ease Gas Prices Mercury Reaches 52 Billion Valuation Amid Fintech Recovery Novartis Upgrades FullYear Outlook on Strong Operational Performance Tennessee Enacts FAIR Rx Act Prohibiting PBM Ownership of Pharmacies TPA and NCPA Applaud South Western Railway One Year After Nationalisation Progress and Reliability Questions Linger Morrisons to Close 100 Stores Amid Rising Cost Pressures from Government Policies Chinas Crypto Underworld Court Cases Reveal Middlemen Evading Crackdown SCNI Q4 2023 Earnings EPS Beats Estimates Despite No Revenue MRDN Q1 2026 Earnings Massive EPS Beat with 107647 Surprise ResMed Q1 2026 Earnings EPS Beats Estimates but Stock Slips IMRX Q1 2026 Earnings EPS Beat Estimates by 183 as Clinical Pipeline Advances Prime Medicine Inc PRME Q1 2026 Earnings WiderthanExpected Loss Highlights PreRevenue Development Phase Iron Horse Acquisitions Rights IRHOR Slips Nearly 6 as Rights Trade Near Support Levels ADSEW Dips to 041 ADSTEC Energy Warrant Faces Resistance After Modest Decline Neumora Therapeutics NMRA Holds Steady at 185 as Consolidation Continues Eaton Vance Municipal Income 2028 Term Trust ETX Hovers Near Support Amid Minimal Volatility OneConstruction Group ONEG Slips 11 Amid Sector Headwinds Key Support Test at 085 GRBK Q1 2026 Earnings Strong BottomLine Beat Despite Modest Stock Dip ZYME Q1 2026 Earnings EPS Misses Estimates as PreRevenue Biotech Reports Wider Loss BFH Q1 2026 Earnings Strong EPS Beat Amidst Stable Operations HOVR Q1 2026 Earnings EPS Misses Estimates PreRevenue Development Continues SDRL Q1 2026 Earnings NarrowerthanExpected Loss Boosts Surprise but Shares Slip Marchex MCHX Q1 2026 Earnings EPS Falls Short of Consensus in Challenging Quarter Hubbell Incorporated Draws Mixed Analyst Ratings Amid Steady Performance YALA Q1 2026 Earnings EPS of 016 Drives 165 Stock Gain Despite Limited Data Kazia Therapeutics KZIA Faces Sharp Decline as Biotech Volatility Resurfaces